Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

Summary & key facts

Researchers ran a carefully controlled study comparing psilocybin therapy with a common antidepressant, escitalopram, in people with moderate to severe depression over a core six-week period. They measured many kinds of intense, short-term psychological experiences that happen during psilocybin sessions. Two kinds of experiences—what people call a “mystical” experience and “ego dissolution” (a strong loosening of the sense of self)—stood out as explaining why psilocybin therapy worked differently than escitalopram. Other intense reactions, such as emotional breakthroughs and strong responses to music during the session, were also linked to bigger improvements in depression. The results support the idea that these acute psychological experiences may help explain how psilocybin therapy reduces depressive symptoms, but the findings are exploratory and don’t prove a final cause-and-effect story yet.

Key facts:

• The study directly compared psilocybin therapy to a common antidepressant, escitalopram, in a carefully controlled trial lasting six weeks.
• Researchers looked at short-term psychological experiences that happen during psilocybin sessions and tested whether those experiences could explain differences in treatment effects.
• Two experiences—mystical-type experiences and ego dissolution (a marked loosening of the usual sense of self)—uniquely helped explain why psilocybin therapy led to better antidepressant effects than escitalopram.
• Higher reports of emotional breakthrough and intense reactions to music during psilocybin sessions were also associated with larger improvements in depression.
• The authors describe the evidence as qualified and exploratory, meaning the results suggest a possible psychological mechanism but do not conclusively prove it and need more study.

Abstract

Abstract The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether acute psychological experiences could meaningfully account for the unique efficacy of PT versus Escitalopram Treatment over a core 6-week trial period. An exploratory-factor-analysis-derived single-factor of depression was used as the outcome. Among a comprehensive set of acute experiences related to psilocybin, so-called “mystical experience” and “ego dissolution” were unique in mediating the effect of treatment condition on depressive response with high specificity. Higher reported levels of mystical experience, emotional breakthrough, and intense responses to music-listening were furthermore associated with greater antidepressant response. These results provide qualified support for the causal mechanistic role of acute psychological experiences in the treatment of depression via PT.

Topics

Chemical synthesis and alkaloids Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies

Categories

Clinical Psychology Psychology Social Sciences

Tags

Antidepressant Anxiety Citalopram Clinical psychology Depression (economics) Economics Escitalopram Hallucinogen Macroeconomics Major depressive disorder Mood Psilocybin Psychiatry Psychology Psychotherapist Treatment-resistant depression

Substances

Psilocybin

Conditions & symptoms

Anxiety Sadness or low mood